Last edition
News about "cancer immunotherapy"
Obsidian Enrols First Patient in Pivotal-Pathway Study of Engineered TIL Therapy
The phase 1/2 Agni-01 cohort will evaluate amsoki-cel in ICI-resistant advanced melanoma, with enrollment expected to conclude by Q1 2027 and topline data anticipated by year-end 2027.<br />
Cancer Immunotherapy | 10/08/2026 | By News Bureau
Innovent Doses First Patient in Pivotal IBI363/TAK-928 CRC Study
Innovent has dosed the first patient in its pivotal IBI363/TAK-928 study, advancing next-generation immunotherapy for colorectal cancer.
Cancer Immunotherapy | 06/08/2026 | By News Bureau | 384
Akeso Doses First Patient in Phase 1b/2 Trial of HER3 ADC for Advanced Lung Cancer
Akeso has dosed the first patient in its Phase 1b/2 AK138D1-201 trial, assessing the HER3-targeted antibody-drug conjugate AK138D1 as monotherapy and in combination with ivonescimab for patients with advanced non-small cell lung cancer.
Cancer Immunotherapy | 30/07/2026 | By News Bureau | 127
WuXi Biologics Receives Brazil GMP Certification for Cancer Therapy Manufacturing
WuXi Biologics has received Brazil ANVISA GMP certification with zero inspection findings, enabling global commercial manufacturing of its innovative cancer immunotherapy.
Cancer Immunotherapy | 02/07/2026 | By News Bureau
Ichnos Glenmark Innovation Unveils Novel Multispecific Antibody Candidate for Solid Tumour Treatment
Ichnos Glenmark Innovation has introduced ISB 2301, a next-generation multispecific antibody designed to activate immune cells and target solid tumours through a multi-mechanism approach aimed at improving cancer treatment outcomes.
Cancer Immunotherapy | 22/05/2026 | By News Bureau | 243
Harbour BioMed Secures FDA IND Clearance for HBM7004 in Advanced Solid Tumors
Harbour BioMed receives US Food and Drug Administration (FDA) IND clearance for HBM7004, a novel B7H4xCD3 bispecific antibody developed on its HBICE platform for advanced solid tumors.
Cancer Immunotherapy | 11/05/2026 | By News Bureau
FDA Grants Priority Review to Astellas and Pfizer's Bladder Cancer Combination Therapy
Astellas and Pfizer’s Padcev-Keytruda combination moves closer to expanded approval, offering a potential new treatment option to reduce recurrence and improve survival in bladder cancer patients.
Cancer Immunotherapy | 21/04/2026 | By News Bureau | 151
OS Therapies files patent for immune-response biomarker linked to cancer immunotherapy
New data from the Phase IIb trial of OST-HER2 shows distinct immune signatures tied to improved survival outcomes, supporting accelerated approval discussions with global regulators.
Cancer Immunotherapy | 20/04/2026 | By News Bureau | 130
Cbio A/S has received regulatory approval to begin a Phase I/IIa trial of novoleucel, a next-generation T-cell therapy, in patients with recurrent Cervical Cancer.
Cancer Immunotherapy | 16/03/2026 | By News Bureau | 191
Oricell Therapeutics Raises USD 70M in Series C1 to Advance CAR-T Therapies for Solid Tumors
The funding will accelerate global expansion and clinical development of Oricell’s CAR-T pipeline, including its lead hepatocellular carcinoma programme Ori-C101.
Cancer Immunotherapy | 13/01/2026 | By News Bureau | 317
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy